Protagonist Therapeutics to Host Conference Call to Announce an Oral Peptide IL-17 Antagonist Development Candidate
Portfolio Pulse from
Protagonist Therapeutics will host a conference call on November 21st to announce its new oral peptide IL-17 antagonist development candidate and share study results.
November 19, 2024 | 12:45 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Protagonist Therapeutics is set to announce a new oral peptide IL-17 antagonist development candidate, which could impact its stock price depending on the study results shared during the conference call.
The announcement of a new development candidate and the sharing of study results could positively impact Protagonist Therapeutics' stock price if the results are promising, as it indicates progress in their product pipeline.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100